MindMed to Participate in the 34th Annual Oppenheimer Healthcare Life Sciences Conference
February 07 2024 - 7:00AM
Business Wire
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (Cboe Canada: MMED)
(the “Company” or “MindMed”), a clinical stage biopharmaceutical
company developing novel product candidates to treat brain health
disorders, announced today that members of the Company’s management
team will participate in the 34th Annual Oppenheimer Healthcare
Life Sciences Conference:
- 34th Annual Oppenheimer Healthcare Life Sciences
Conference
- Format: Presentation
- Date and Time: Tuesday, February 13, 2024 at 10:00 am EST
- Webcast Link: 34th Annual Oppenheimer Healthcare Life Sciences
Conference
Audio webcasts and replays of available presentations will be
accessible on MindMed’s Investor Relations website for up to 90
days following each event.
About MindMed
MindMed is a clinical stage biopharmaceutical company developing
novel product candidates to treat brain health disorders. Our
mission is to be the global leader in the development and delivery
of treatments that unlock new opportunities to improve patient
outcomes. We are developing a pipeline of innovative drug
candidates, with and without acute perceptual effects, targeting
the serotonin, dopamine, and acetylcholine systems.
MindMed trades on NASDAQ under the symbol MNMD and on the Cboe
Canada exchange (formerly the NEO Exchange) under the symbol
MMED.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240207998518/en/
For Media: media@mindmed.co For Investors:
ir@mindmed.co
Mind Medicine MindMed (NASDAQ:MNMD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Mind Medicine MindMed (NASDAQ:MNMD)
Historical Stock Chart
From Apr 2023 to Apr 2024